m1A-MAP-seq Service: Single-Base m1A RNA Methylation Mapping

Q: Can this method detect m1A on highly structured non-coding RNAs like circRNAs or tRNAs?

Yes. Traditional RNA-seq often fails on tRNAs due to their rigid secondary structures and heavy baseline modifications, which block reverse transcription entirely. Our optimized sample preparation involves specific thermal denaturation and modified adapter ligation protocols that provide comprehensive full-molecule coverage, enabling robust m1A detection across mRNA, tRNA, rRNA, lncRNA, and circRNA.

Q: What is the difference in bioinformatics outputs between standard MeRIP and MAP-seq?

While MeRIP-seq provides regional peak density indicating the general vicinity of methylation (useful for broad screening), m1A-MAP-seq delivers exact single-base position annotations. This enables highly precise sequence motif extraction (identifying the exact nucleotides flanking the m1A) and provides strict mismatch-rate validation metrics that are required for top-tier journal submissions.

Q: If my starting RNA amount is lower than the recommended minimum, can I still use this service?

m1A-MAP-seq requires higher input than standard RNA-seq because the sample must be split into Input, Demethylase (+), and Demethylase (-) groups after antibody enrichment. However, for highly precious samples, our technical team can evaluate custom low-input protocols. We strongly advise requesting a technical consultation to assess your specific sample metrics before proceeding.

Welcome to our state-of-the-art m1A-MAP-seq service, designed to propel your RNA epigenetics research from regional estimates to absolute single-nucleotide certainty. By leveraging advanced AlkB demethylase treatment, we offer a robust "turnkey" solution for mapping N1-methyladenosine modifications. Our service is engineered to overcome the historical bottlenecks of traditional antibody-based screening, empowering your complex mechanistic studies with top-tier, verifiable, and publication-ready data.

Core Service Advantages:

True Single-Base Precision: Exact nucleotide mapping via misincorporation-assisted profiling.
Rigorous False-Positive Control: Mandatory Demethylase (+/-) and Input parallel sequencing.
Comprehensive RNA Coverage: Robust detection across mRNA, tRNA, rRNA, and non-coding RNAs.
Complex Sample Handling: Proven track record with low-yield tissues and non-model organism extractions.

Get a Quote

Right-aligned high-tech illustration showing a magnifying glass zooming in on a single RNA nucleotide, highlighting the exact m1A modification site against a transcript background.

Overview

Decoding m1A at Single-Nucleotide Precision

N1-methyladenosine (m1A) is a highly dynamic and critical RNA modification that fundamentally alters the physicochemical properties of RNA. Because the methyl group at the N1 position of adenine adds a positive charge and disrupts normal Watson-Crick base pairing, m1A dramatically impacts RNA structural stability, protein-RNA interactions, and translation efficiency. While m1A is abundant and relatively stable in tRNA and rRNA, its presence in mRNA and non-coding RNAs is often transient, lowly abundant, and highly context-dependent, making accurate detection a persistent challenge in epigenetics.

Traditional antibody-based screening methods often lack the precise resolution required for deep mechanistic studies, typically yielding peaks that span 100 to 200 nucleotides. This regional data is insufficient when researchers need to perform targeted functional validations, such as designing specific guide RNAs for CRISPR editing.

Our m1A-MAP-seq service overcomes this limitation by utilizing an advanced AlkB demethylase treatment paired with a misincorporation-assisted profiling strategy. During standard reverse transcription, the bulky m1A modification causes the reverse transcriptase enzyme to stall or introduce mutations (mismatches). By systematically treating a parallel RNA aliquot with the wild-type E. coli AlkB demethylase—which efficiently removes the m1A methyl group—we can compare the sequencing read mismatch rates between treated and untreated samples. By capturing these precise reverse transcription misincorporations induced by m1A, we deliver true single-base resolution data.

This unparalleled precision empowers researchers utilizing broad RNA Methylation Services to transition seamlessly into exact nucleotide validation.

Diagram illustrating the mechanism of AlkB demethylase treatment and RT misincorporation.

Applications

Key Applications in RNA Epigenetics Research

Mapping m1A at a single-nucleotide level opens new avenues for understanding complex biological systems. Our service is tailored to support a wide range of advanced research applications, ensuring your data directly translates to biological insights:

Disease Mechanism Elucidation

Aberrant m1A methylation is heavily implicated in various pathologies, including metabolic syndromes and tumorigenesis. By pinpointing the exact location of m1A sites on critical oncogenes or tumor suppressor transcripts, researchers can map out the precise regulatory networks driving disease progression. This allows for the identification of specific reader, writer, and eraser proteins that may serve as novel downstream functional targets.

Translational Regulation & Ribosome Dynamics

Because m1A disrupts base pairing, its presence in the 5' UTR or CDS of mRNA can create structural roadblocks or alter start codon recognition, fundamentally shifting translation efficiency. Furthermore, m1A at position 58 of eukaryotic initiator tRNA is essential for maintaining initiator tRNA stability. Single-base mapping allows researchers to correlate specific methylation events with polysome profiling data to understand exactly how translation is modulated under cellular stress.

Targeted Mutagenesis Guidance

When transitioning from bioinformatics to in vitro or in vivo models, researchers need exact genomic coordinates. Regional m1A peaks make it impossible to know which specific adenine to mutate. Our m1A-MAP-seq data provides the exact single-base coordinates required to design precise CRISPR/Cas9 or base-editing experiments, allowing you to validate the physiological impact of individual m1A sites with absolute confidence.

High-Resolution Biomarker Discovery

For translational research, global methylation levels often lack the specificity needed for precise molecular profiling. Identifying unique, single-nucleotide epigenetic signatures—such as a specific m1A modification on a circulating non-coding RNA—offers a much more precise indicator for mapping disease pathways and molecular phenotyping.

Decision Guide

m1A-MAP-seq vs. m1A-MeRIP-seq: A Strategic Guide

Selecting the right sequencing technology is crucial for optimizing your research budget and achieving publication goals. The choice between immunoprecipitation and misincorporation profiling should be dictated by the current phase of your research. We highly recommend a "Screen & Validate" strategy:

Global Screening: Utilize the m1A-MeRIP-seq Service for initial broad profiling across large sample cohorts. This is the most cost-effective way to identify general areas of differential methylation between wild-type and disease models.
Targeted Validation: Transition to m1A-MAP-seq to confirm specific functional target sites and resolve the precise nucleotide position before commencing with complex mechanistic modeling.

Feature	m1A-MeRIP-seq	m1A-MAP-seq
Resolution	Regional peak (~100-200 nt)	True single-nucleotide precision
Mechanism	Antibody-based IP enrichment	AlkB demethylation + RT misincorporation
Primary Goal	Global transcriptomic screening & discovery	Precise site validation & functional mechanism
False Positive Rate	Moderate (antibody cross-reactivity)	Extremely low (strict internal controls)
Input Volume	Standard	Generally higher input required due to multi-arm prep

Workflow

Rigorous Workflow & Demethylase-Controlled QC

Horizontal flowchart showing RNA fragmentation, anti-m1A antibody enrichment, splitting into Input, Demethylase (+), and Demethylase (-) groups, followed by sequencing and bioinformatic mismatch alignment.

A major challenge in single-base mapping is differentiating genuine m1A misincorporations from natural single nucleotide polymorphisms (SNPs) or reverse transcriptase background errors. Our optimized workflow integrates a mandatory, strictly controlled experimental design to virtually eliminate false positives.

RNA Fragmentation & Primary Enrichment: Total RNA is carefully fragmented to ~150nt to ensure optimal sequencing coverage. The fragments are first enriched using a highly specific anti-m1A antibody. Crucially, an untreated portion of the total RNA is retained as the Input control to map baseline expression levels and genomic SNPs.
Enzymatic Branching (The Critical QC Step): The antibody-enriched fragments are divided into two parallel, strictly controlled reactions:
- Demethylase (+): Treated with AlkB demethylase (an alpha-ketoglutarate and iron-dependent dioxygenase) to efficiently erase the m1A marks, allowing the reverse transcriptase to read through normally, substituting standard adenine.
- Demethylase (-): Left untreated, forcing the reverse transcriptase to stall or misincorporate (typically inserting a complementary thymine, cytosine, or guanine instead of the expected thymine) at the exact site of the m1A modification.
Library Preparation & High-Depth Sequencing: Specialized adapter ligation and reverse transcription protocols are used to capture highly structured RNAs (like tRNAs) without bias. The libraries undergo high-depth Illumina sequencing.
Bioinformatic Misincorporation Calling: By directly comparing the mismatch rates at specific adenine loci between the Demethylase (+) and Demethylase (-) libraries during bioinformatic alignment, we isolate true m1A-induced mutation signals with absolute statistical confidence, filtering out any background enzymatic noise.

Bioinformatics

Publication-Ready Bioinformatics Deliverables

Our expert bioinformatics team bridges the gap between raw sequencing data and high-impact publications. We do not just provide raw fastq files; we deliver a comprehensive suite of analytical data tailored for deep mechanistic parsing.

Minimum Deliverables:

Comprehensive Raw Data Quality Control (FastQC) and adapter trimming.
High-fidelity read alignment to the reference genome utilizing mismatch-tolerant algorithms.
Demethylase-controlled misincorporation site calling and statistical error rate quantification.
Single-base m1A annotation across the entire transcriptome.

Optional Advanced Add-ons for Mechanistic Insight:

m1A Peak Distribution Analysis: Visualizing methylation density across distinct transcript architectures.
Differential Methylation Clustering: Hierarchical heatmap analysis grouping distinct m1A sites.
m1A Motif Analysis: Generating sequence logos to identify consensus motifs surrounding the exact methylation sites.
Functional Enrichment: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway mapping.

Demo Results

Publication-Ready Demo Results

Our expert bioinformatics pipeline translates complex single-base mapping data into high-impact, publication-ready visualizations. Below are representative deliverables from our m1A-MAP-seq analysis framework combined into a single view:

Composite panel of bioinformatics demo results including peak density, heatmap clustering, sequence motif, genome browser tracks, and pathway enrichment.

m1A Peak Density Distribution: Visualizes the accumulation of m1A modifications across different transcript segments (5'UTR, CDS, 3'UTR). This helps identify regional methylation preferences and broad transcriptomic architectures affected by the epigenetic mark.
Differential Methylation Clustering: A hierarchical heatmap analysis that clusters distinct m1A sites between control and treated/mutant samples. This instantly highlights systemic epigenetic shifts and clearly separates biological replicates based on their modification profiles.
m1A Motif Analysis: Extracts and visualizes consensus sequence logos (e.g., GGACA) surrounding the exact methylation sites. Pinpointing the sequence environment is critical for predicting specific methyltransferase or reader protein binding preferences.
m1A Site Visualization Tracks: Genome browser tracks directly comparing Input and m1A IP signals (alongside the critical demethylase +/- libraries). This track visualization validates precise single-nucleotide misincorporation events and enrichment at targeted gene loci.
GO and KEGG Pathway Enrichment: Maps heavily modified transcripts to their functional Gene Ontology terms and KEGG pathways, connecting molecular-level epigenetic changes to broad biological phenotypes and signal transduction pathways.

Sample Requirements

We recognize that advanced epigenetic studies often rely on precious, hard-to-obtain samples. We have extensive experience processing challenging materials, including low-yield preclinical tissues, complex non-model organisms, and highly degraded samples. If your laboratory struggles with primary RNA isolation, we highly recommend utilizing our Complex Sample RNA Extraction capabilities to ensure maximum yield and purity before sequencing begins.

All samples must be shipped in 1.5 mL centrifuge tubes, securely sealed with parafilm, and transported on dry ice to ensure complete RNA integrity.

Sample Type	Required Amount	Shipping	Storage & Preparation Notes
Cell Cultures	≥ 2 × 10^7 cells	Dry Ice	Snap-freeze in liquid nitrogen, store at -80°C. Avoid repeated freeze-thaw cycles.
Fresh Tissues	100 mg – 1 g	Dry Ice	Cut into small pieces (5-10 mg), snap-freeze in liquid nitrogen, store at -80°C.
Total RNA	30 – 300 μg	Dry Ice	Dissolve in ethanol or RNase-free H2O, store at -80°C. Strict QC: OD260/280 ≥ 1.8; OD260/230 ≥ 1.5; RIN ≥ 7 (or 28S:18S ≥ 1.5); intact bands without obvious degradation.
Body Fluids & Others	Please inquire	Dry Ice	Contact our technical team for specific preclinical collection protocols.

Case Study

Case Study: N1-Methyladenosine Methylation in tRNA Drives Liver Tumourigenesis

N1-Methyladenosine Methylation in tRNA Drives Liver Tumourigenesis

Background: Hepatocellular carcinoma (HCC) is driven by complex molecular mechanisms and is characterized by high rates of metastasis and recurrence. While RNA modifications are known to play a role in cancer progression, researchers sought to investigate the specific epigenetic networks controlling tumor stem cell self-renewal. The team required an exact, single-base map of m1A modifications to identify the functional downstream targets responsible for maintaining the oncogenic state.

Methods: Utilizing advanced single-base RNA methylation sequencing strategies alongside RNA-seq, the study comprehensively profiled m1A levels across mammalian tumor models and matched normal control tissues. The analysis specifically targeted the expression and regulatory capacity of the TRMT6/TRMT61A methyltransferase complex. Total RNA was extracted, highly enriched for m1A using specific antibodies, and subjected to rigorous demethylase-assisted misincorporation profiling to generate high-confidence single-base topological maps.

Results: The high-depth sequencing and subsequent bioinformatics data revealed that TRMT6/TRMT61A-mediated m1A methylation is significantly and specifically upregulated in a precise subset of tRNAs in HCC models. As clearly visualized in Figure 1 of the published data, the precise single-nucleotide mapping of these modifications across the tRNA landscape highlighted their functional role in directly increasing the translation efficiency of specific oncogenic targets, notably the PPARδ pathway.

Conclusion: This highly precise single-base profiling successfully mapped the dynamic modification landscape of tRNAs, providing critical, verifiable evidence that m1A upregulates cholesterol synthesis to activate Hedgehog signaling. The exact spatial data generated by the MAP-seq workflow was essential for the subsequent CRISPR and functional rescue experiments, definitively proving that m1A directly drives tumourigenesis.

Source: Wang, Y., Wang, J., Li, X., et al. "N1-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism." Nature Communications 12, 6314 (2021).

FAQ

Frequently Asked Questions (FAQ)

Q: How does m1A-MAP-seq definitively avoid background sequencing errors from the reverse transcriptase itself?

A: Reverse transcriptase enzymes naturally possess a baseline error rate. By implementing a strict Demethylase (+) versus Demethylase (-) parallel library preparation, we bioinformatically subtract this background noise. If a mismatch appears at the same adenine locus in both the treated and untreated libraries, it is flagged as a genomic SNP or natural RT error. A true m1A site is only called when a mismatch is highly prevalent in the untreated library but disappears (reverts to A) in the AlkB-treated library.

Q: Can this method detect m1A on highly structured non-coding RNAs like circRNAs or tRNAs?

Q: What is the difference in bioinformatics outputs between standard MeRIP and MAP-seq?

Q: What is the recommended sequencing depth for m1A-MAP-seq compared to standard RNA-seq?

A: Due to the necessity of splitting the enriched RNA into Demethylase (+) and Demethylase (-) parallel libraries, and the requirement to capture rare misincorporation events with high statistical confidence, m1A-MAP-seq typically requires a significantly higher sequencing depth than standard transcriptomic profiling. We generally recommend at least 40-50 million reads per library to ensure accurate base-resolution calling, especially for lowly expressed transcripts or transient modifications.

Q: If my starting RNA amount is lower than the recommended minimum, can I still use this service?

References

Wang, Y., Wang, J., Li, X., et al. "N1-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism." Nature Communications 12, 6314 (2021).
Safra, M., Sas-Chen, A., Nir, R. et al. "The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution." Nature 551, 251–255 (2017).
Li, X., Xiong, X., Wang, K., et al. "Transcriptome-wide mapping reveals reversible and dynamic N1-methyladenosine methylome." Nature Chemical Biology 12, 311–316 (2016).

Compliance / Disclaimer / Research Use Only
The services, technologies, and data provided herein are strictly for Research Use Only (RUO). They are not intended, validated, or approved for use in diagnostic procedures, clinical decision-making, or therapeutic applications.

! For research purposes only. Not intended for clinical diagnosis, treatment, or individual health assessments.